Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1214920130190010031
Soonchunhyang Medical Science
2013 Volume.19 No. 1 p.31 ~ p.33
Bortezomib Induced Tumor Lysis Syndrome in Multiple Myeloma
Yu Shin-Ae

Ryu Sung-Woo
Kim Kyoung-Ha
Kim Se-Hyung
Lee Nam-Su
Park Seong-Kyu
Won Jong-Ho
Abstract
The tumor lysis syndrome (TLS) commonly occurs in the lymphoproliferative disorder, either spontaneously or in response to therapy. TLS is uncommon in multiple myeloma. However, with the use of bortezomib in the treatment of multiple myeloma, cases of TLS have been reported. We report here threepatients who presented with TLS after the administration of bortezomib. Two of them presented mild symptoms and recovered with hydration only. However, death of the other patient was associated with TLS. We should monitor patients who had high tumor burden, especially in early phase of bortezomib therapy and appropriate prophylaxis for high risk patient is also needed.
KEYWORD
Bortezomib, Multiple myeloma, Tumor lysis syndrome
FullTexts / Linksout information
 
Listed journal information
KoreaMed